Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865969 · ClinicalTrials.gov registry record · Phase 2
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
A Phase 2 study of Peripheral T-Cell Lymphoma, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 20
- Study locations
NCT00865969 is a Phase 2 study of Peripheral T-Cell Lymphoma that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 129 participants, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT00865969, a Phase 2 study of Peripheral T-Cell Lymphoma, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior systemic therapy.
Conditions Studied
Interventions
- DRUG Belinostat
Study Locations (20)
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
- Kellogg Cancer Care Center - Evanston
- Illinois Cancer Specialists/Cancer Care & Hematology Specialists of Chicagoland - Niles
- Illinois CancerCare, P.C. - Peoria
California
- City of Hope National Medical Center - Duarte
- Wilshire Oncology Medical Group, Inc - La Verne
- Comprehensive Cancer Center - Palm Springs
Connecticut
- Yale Cancer Center-Section of Medical Oncology - New Haven
- Oncology Associates of Bridgeport - Trumbull
Massachusetts
- Dana Farber Cancer Institute - Boston
- Boston University Medical Center - Boston
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Health System - Detroit
Missouri
- Saint Louis University - St Louis
- Washington University School of Medicine - St Louis
Florida
- Boca Raton Clinical Research Associates - Boca Raton
Georgia
- Georgia Health Sciences University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2008-12-15 |
| Est. Completion | 2014-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865969
The ClinicalTrials.gov registry entry for NCT00865969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (26% higher). The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Belinostat is the first listed.
NCT00865969 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Illinois, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00865969 about?
NCT00865969 is a clinical study titled "Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma". The purpose of this study is to assess efficacy and safety of belinostat in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior systemic therapy.
What is the current status of trial NCT00865969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2008-12-15. Estimated completion is 2014-10-27.
What conditions does trial NCT00865969 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT00865969?
The interventions under investigation include: Belinostat (DRUG).
Who is sponsoring clinical trial NCT00865969?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00865969 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.